Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Chemoradiation for Esophageal and GEJ Adenocarcinoma
NCT02962063Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2016
- Primary completion
- Nov 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Unacceptable toxicity at 1 year and Pathologic complete response rate at 1 year. Started Nov 2016; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02962063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962063.